Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Compass Therapeutics, Inc. $CMPX

Key Points

• Connor Clark & Lunn purchased 523,777 shares of Compass Therapeutics in the second quarter, valued at approximately $1.15 million and representing about 0.29% of the company. Institutional investors and hedge funds collectively own 68.43% of CMPX.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $11.77, despite ratings ranging from strong sell to strong buy.
• CMPX opened at $2.40, well below its one-year high of $6.88, and reported a quarterly loss of $0.13 per share versus the $0.11 consensus estimate. Analysts expect a full-year loss of approximately $0.47 per share.

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 523,777 shares of the company's stock, valued at approximately $1,147,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.29% of Compass Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Compass Therapeutics by 224.9% in the first quarter. Bank of America Corp DE now owns 865,613 shares of the company's stock valued at $4,579,000 after buying an additional 599,179 shares during the period. Royce & Associates LP acquired a new stake in Compass Therapeutics during the 4th quarter worth approximately $1,536,000. Seven Fleet Capital Management LP acquired a new stake in Compass Therapeutics during the 4th quarter worth approximately $3,054,000. NEXTBio Capital Management LP bought a new stake in Compass Therapeutics during the 4th quarter worth approximately $5,982,000. Finally, Sofinnova Investments Inc. grew its holdings in Compass Therapeutics by 65.9% during the 4th quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company's stock worth $18,072,000 after acquiring an additional 1,336,560 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research note on Monday, June 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Piper Sandler increased their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They set a "buy" rating and a $5.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Compass Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $11.77.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $2.40 on Monday. The stock has a market capitalization of $432.21 million, a PE ratio of -6.00 and a beta of 0.92. The business's 50 day simple moving average is $2.19 and its 200 day simple moving average is $3.44. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts expect that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.